This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 442 results found since Jan 2013.

Cook Medical receives FDA approval for gastrointestinal medical device
Cook Medical has received FDA approval to market in the U.S. a device known as Hemospray that treats gastrointestinal bleeding. The device was developed at Cook's Winston-Salem operations, where the company employs 640 people and ranks as the Triad's sixth-largest life science employer. Based in Bloomington, Indiana, the company employs more than 10,000 worldwide, some 70 percent of whom are located in the U.S. Hemospray, a single-use endoscopic hemostat, treats gastrointestinal bleeding by injecting…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2018 Category: Pharmaceuticals Authors: Luke Bollinger Source Type: news

Graphene-kaolin composite sponge for rapid and riskless hemostasis
Publication date: 1 September 2018 Source:Colloids and Surfaces B: Biointerfaces, Volume 169 Author(s): Yuping Liang, Congcong Xu, Guofeng Li, Tianchi Liu, Jun F. Liang, Xing Wang Kaolin is an effective and safe hemostatic agent for hemostasis. However, its ontic powder is difficult to use in actual practice. To develop a wieldy and powerful hemostat, composite strategy is usually a good choice. Herein, we developed a graphene-kaolin composite sponge (GKCS), synthesized with graphene oxide sheets, linker molecules and kaolin powders through a facile hydrothermal reaction. SEM observations support that GKCS has a porous st...
Source: Colloids and Surfaces B: Biointerfaces - May 17, 2018 Category: Biochemistry Source Type: research

Cook Medical wins FDA de novo nod for Hemospray
Cook Medical said yesterday it won FDA de novo clearance for its Hemospray endoscopic hemostat designed for treating bleeding in the gastrointestinal tract. The Hemospray product won indications from the FDA for treating non-variceal GI bleeds, the Bloomington, Ind.-based company said. Hemospray is a single-use device designed to deliver an aerosolized spray of a mineral blend to a bleeding site during endoscopic procedures, and can cover large areas including ulcers and tumors, according to an FDA release. “We are extremely pleased to receive this approval to market from FDA. We have worked diligently to bring a di...
Source: Mass Device - May 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Endoscopic / Arthroscopic Food & Drug Administration (FDA) Regulatory/Compliance Cook Medical Source Type: news

Graphene-kaolin composite sponge for rapid and riskless hemostasis.
Abstract Kaolin is an effective and safe hemostatic agent for hemostasis. However, its ontic powder is difficult to use in actual practice. To develop a wieldy and powerful hemostat, composite strategy is usually a good choice. Herein, we developed a graphene-kaolin composite sponge (GKCS), synthesized with graphene oxide sheets, linker molecules and kaolin powders through a facile hydrothermal reaction. SEM observations support that GKCS has a porous structure, and EDS mapping further confirms that kaolin powders are embedded in graphene sheets. Once GKCS is exposed to bleeding, plasma is quickly absorbed inside ...
Source: Colloids and Surfaces - May 8, 2018 Category: Biotechnology Authors: Liang Y, Xu C, Li G, Liu T, Liang JF, Wang X Tags: Colloids Surf B Biointerfaces Source Type: research

Baxter inks partnership deal with International Society of Nephrology
Baxter (NYSE:BAX) said today it inked a partnership deal with the International Society of Nephrology looking to advance awareness and therapy for patients with chronic kidney disease, primarily in low and middle-income countries where the disease is growing the fastest. In the collaborative partnership , Deerfield, Ill.-based Baxter and the ISN will look to support further therapy research and education about chronic kidney disease, while also looking to develop better care models at lower costs. “ISN and Baxter’s collaboration aims to address the urgent and growing challenge kidney disease is causing healthcare ...
Source: Mass Device - May 2, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Baxter Source Type: news

4 Trends Advancing Medtech
For the past 20 years, the Medical Design Excellence Awards have celebrated medical products that improve the quality and accessibility of healthcare. Our finalists this year carry on this tradition, while also keeping in step with today’s high-tech digital and consumer trends. With the help of our esteemed jurors, we have identified four key trends in this year’s group of finalists: risk reduction; faster, more-efficient healthcare delivery; the influence of the Internet of Things; and the consumerization of healthcare. We’ve been tracking a few of these trends in past awards programs, so they’re not necessarily n...
Source: MDDI - April 27, 2018 Category: Medical Devices Authors: Daphne Allen Tags: MD & M East (New York) Design Source Type: news

Cohera Medical Inc. ® Awarded Patent on its Biodegradable Sealant Technology
Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company a notice of allowance on its patent application, titled “SILANE-CONTAINING MOISTURE-CURABLE TISSUE SEALANT”.The patent relates to a novel 100% synthetic sealant with several potential surgical applications.  The sealant covered by the patent, Sylys ® Surgical Sealant, is highly elastic, and has good bonding strength to internal tissues.  In addition, the sealant is easy to prepare and apply in the operating theatre and ...
Source: Medical Hemostat - April 25, 2018 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Baxter closes $153m hemostat, sealant asset buy from Mallinckrodt
Baxter (NYSE:BAX) said today that it closed the $153 million acquisition of hemostat and sealant assets from Mallinckrodt Pharmaceuticals (NYSE:MNK). Baxter announced in January its plan to acquire the stand-alone recombinant thrombin Recothrom and Preveleak surgical sealant for vascular reconstruction. “We are excited to add both Recothrom and Preveleak to our portfolio of hemostats and sealants to offer surgeons additional options that address different situations when intraoperative bleeding can occur,” advanced surgery president Wil Boren said in prepared remarks. “Our top priority right now is wor...
Source: Mass Device - March 19, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Surgical Vascular Wall Street Beat Baxter Mallinckrodt Source Type: news

Convesaid, a Hemostat Powder Spray That Can ’t Cause Embolisms
Team Consulting, a firm based out of an old barn in Cambridge, UK that develops medical devices, one being the EpiPen, has now come up with a hemostat powder sprayer that cannot cause embolisms. When spraying a powder onto a leaking vein, the air tha...
Source: Medgadget - March 16, 2018 Category: Medical Devices Authors: Editors Tags: Cardiac Surgery Emergency Medicine Thoracic Surgery Vascular Surgery Source Type: blogs

Recombinant batroxobin-coated nonwoven chitosan as hemostatic dressing for initial hemorrhage control.
In conclusion, hemostasis can be improved by combining a chitosan-based nonwoven dressing with other agents, and rBat-coated chitosan-based nonwoven dressings have enormous potential to improve blood coagulation. PMID: 29514041 [PubMed - as supplied by publisher]
Source: International Journal of Biological Macromolecules - March 4, 2018 Category: Biochemistry Authors: Seon GM, Lee MH, Kwon BJ, Kim MS, Koo MA, Seomun Y, Kim JT, Kim TH, Park JC Tags: Int J Biol Macromol Source Type: research

Axiostat is India ’ s first entry on the U.S. hemostat market
Indian medical device maker Axio Biosolutions became the first Indian company with a wound care product cleared by the FDA, according to a press release from the company posted yesterday. The federal watchdog granted 510(k) clearance to Axio’s Axiostat chitosan hemostatic dressing, which is cleared as an over-the-counter product to stop external bleeding. The dressing is designed to stop uncontrollable bleeding within two to three minutes of application, and is used by the Indian armed forces, the company said. “The FDA clearance of Axiostat in the US is a major milestone in our journey so far. This is a valida...
Source: Mass Device - March 1, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Blood Management Regulatory/Compliance Wound Care axiobiosolutions Source Type: news

Tricuspid repair firm 4Tech taps ex-Boston Scientific execs for CEO, CMO | Personnel Moves for Feb. 27, 2018
4Tech said last week that it named a pair of BSX veterans as its new CEO and CMO, with onetime chief Mike Ennen stepping away for “family reasons.” Galway, Ireland-based 4Tech said former Boston transcatheter aortic valve GM Tom Fleming is slated to take the reins from Thoratec vet Ennen as president & CEO in March. The company, which is developing the TriClinch Coil transcatheter tricuspid valve repair device, also said that Dr. Keith Dawkins, Boston’s ex-global medical chief, was named CMO effective Feb. 22.  Z-Medica lures ex-Hologic COO Compton Z-Medica said it named former Hologic (NSDQ:HOLX...
Source: Mass Device - February 27, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Replacement Heart Valves Wall Street Beat 4Tech Check-Cap CHF Solutions Inc. imaginmedical imagionbiosystems Invacare LimFlow orthosalespartners personnel-moves Teleflex Source Type: news

Postoperative cytological findings from the use of the Integran microfibrillar collagen hemostatic matrix in conization
This article is the first report describing cervical cytology findings associated with Integran use.
Source: Diagnostic Cytopathology - February 21, 2018 Category: Pathology Authors: Shinji Toyoda, Hiroshi Okada, Hideo Tsujino, Yoshinori Takeda, Atsushi Sugiura, Yoshio Itani, Tsunekazu Kita, Eiwa Ishida Tags: BRIEF REPORT Source Type: research

SURGICEL & #194; & #174; Powder Absorbable Hemostat is used in surgeries.
SURGICEL® Powder Absorbable Hemostat is used for broad-surface oozing and stops bleeding fast. Unit is suitable for gynecologic, oncologic, cardiovascular and general procedure applications. Product offers bactericidal activity in vitro against MRSA, MRSE, VRE, PRSP, E Coli pathogens.This story is related to the following:Hemostats
Source: Industrial Newsroom - Health, Medical and Dental Supplies - January 10, 2018 Category: Medical Devices Source Type: news

New Absorbable Adjunctive Hemostat From Ethicon Helps Surgeons Control Disruptive Bleeding More Efficiently
SURGICEL® Powder is the next innovation in bleeding management designed to help improve operating efficiency SOMERVILLE, N.J., Jan. 9, 2018 -- (Healthcare Sales & Marketing Network) -- Ethicon*, part of the Johnson & Johnson Medical Devices Compani... Devices, Surgery, Product Launch Ethicon, Johnson & Johnson, SURGICEL, ABSORBABLE HEMOSTAT, hemostat
Source: HSMN NewsFeed - January 9, 2018 Category: Pharmaceuticals Source Type: news